Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies

Urology
Sender HerschornZ Guan

Abstract

To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg in men with overactive bladder. This was a subanalysis of pooled data from 358 men enrolled in 2 double-blind, placebo-controlled phase III trials. Subjects with frequency and urgency or urgency urinary incontinence (UUI) were randomized to fesoterodine 4 mg, fesoterodine 8 mg, or placebo for 12 weeks. Efficacy endpoints included bladder diary variables and subject-reported treatment response. By week 12, men treated with fesoterodine 4 or 8 mg had significantly greater median percentage improvements in micturition frequency, urgency episodes, and UUI episodes versus placebo and significantly greater percentages reported a treatment response versus placebo. Significant increases in mean voided volume (MVV) per micturition versus placebo occurred with fesoterodine 8 mg only. At week 12, fesoterodine 8 mg was significantly more efficacious than fesoterodine 4 mg in improving UUI episodes and MVV per micturition. The most commonly reported adverse events with fesoterodine 4 and 8 mg were dry mouth (12.5% and 37.7% vs 5.6% with placebo) and constipation (2.5% and 8.8% vs 0.8% with placebo). Symptoms suggestive of urinary retention were reported in 0.8%, 0.8...Continue Reading

References

Jun 9, 1992·Biochemical Pharmacology·A GómezF Sanchez de la Cuesta
Jun 18, 2003·World Journal of Urology·W F StewartA J Wein
Nov 16, 2006·JAMA : the Journal of the American Medical Association·Steven A KaplanZhonghong Guan
Oct 17, 2007·The Journal of Urology·Victor W NittiTamara Bavendam
Mar 18, 2008·Urology·Vik KhullarZhonghong Guan
Jun 20, 2008·BJU International·Con J KelleherZoe Kopp
Aug 18, 2009·The Journal of Urology·Elisa Martín-MerinoClaus G Roehrborn
Aug 21, 2009·Neurourology and Urodynamics·W F StewartA Dilley
Jan 1, 2006·Neurourology and Urodynamics·Paul AbramsPeter Sand

❮ Previous
Next ❯

Citations

Nov 16, 2013·Current Opinion in Urology·João SilvaFrancisco Cruz
Jul 12, 2012·Der Urologe. Ausg. A·F StrittmatterC Gratzke
Nov 12, 2013·Expert Opinion on Drug Metabolism & Toxicology·Stephen Mock, Roger R Dmochowski
Oct 30, 2013·Current Medical Research and Opinion·Howard B GoldmanFady Ntanios
Mar 25, 2011·Current Medical Research and Opinion·Jacques CorcosUNKNOWN Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group
Mar 2, 2011·Current Medical Research and Opinion·Harriette ScarperoMartin Carlsson
Dec 15, 2015·International Journal of Surgery·Haitham AbdelmotelebMarcus J Drake
Jan 8, 2011·International Journal of Clinical Practice·S A KaplanZ Guan
Jul 25, 2012·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·V SchulerU von Mandach
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Priya MadhuvrataE Jean C Hay-Smith
Jan 17, 2017·Current Urology Reports·Matthew C MossAlex Gomelsky
Feb 18, 2021·Deutsches Ärzteblatt International·Arkadiusz Miernik, Christian Gratzke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.